Based on these previous findings, we aimed to investigate whether SS-b2 inhibits PLC development, particularly inflammation-related liver cancer, by targeting STK4/IRAK1 through in vivo and in vitro experiments. This evidence concerns the gene HSPG2 and liver cancer.